Press

news-magnifyglass.png

Crown Bioscience Announces Launch of OmniScreen Cell Panel Screening Platform

July 8, 2016

(Santa Clara, Calif., July 07 2016) Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, is announcing the launch of the OmniScreen cell panel screening platform, a new versatile cell line screening service for oncology drug discovery programs.

OmniScreen™ will be run on a cycled schedule every three months, allowing clients to select from three panels of cell lines that are most suitable for their needs. This approach provides a more cost-effective solution for researchers because it runs multiple compounds simultaneously on a fixed schedule. The service also increases the flexibility of screening and template designs, allowing subpanels of cell lines to meet the needs of a wider range of clients.

“Researchers enrolling their compounds in OmniScreen will be given access to a private, secure online account where they can observe their data in real time to generate reports for further analysis,” said Qian Shi, vice president of cancer pharmacology and in vitro cancer biology at CrownBio.

OmniScreen includes three specialty subpanels, including OmniPanel, XenoSelectPanel and RNAseq Panel. OmniPanel includes a total of 352 cancer cell lines, supporting expedited screening for drug response across genomically diverse cancer lines. XenoSelect includes 158 cancer cell lines, from which CrownBio has already developed corresponding xenograft models, to move lead compounds from in vitro to in vivotesting. RNAseq Panel includes 139 cancer cell lines that are better aimed to biomarker discovery.

“Given its flexibility and cost-effectiveness, OmniScreen will change the way our clients evaluate their compounds,” Shi said. “By accessing detailed genomic data in real time, we can provide a path to convert lead compounds into clinical candidates.”

For more information on OmniScreen and CrownBio’s commitment to furthering the field of cell panel screening technology, visit www.crownbio.com.

About Crown Bioscience Inc.

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.